General Pharmaceutical Council determination — substantive hearing
GPhC suspended Mohammed Amier for twelve months over wholesaling dishonesty in 2024
The committee found repeated dishonesty but rejected one disputed allegation. It recognised remorse and positive clinical references, and imposed suspension with review rather than removal.
MedicWatch editorial · Published 26 March 2024 · Updated 22 September 2026
Suspension (suspended from practice) — 1 year
Data last checked: 22 September 2026Report a correction
What does “suspended from practice” mean?
The regulator imposed a fixed-term suspension in this decision. Its start date, appeal provisions and any later review affect whether it is currently in force. Check the official register for the practitioner's current status.
Concerning Mohammed Amier, pharmacist (General Pharmaceutical Council 2076769).
Decision date: 26 March 2024 · Hearing started 18 March 2024 and ended 26 March 2024
This sanction period has elapsed.
In plain English
The GPhC committee suspended Mohammed Amier for twelve months in March 2024 after finding repeated dishonesty in obtaining medicines for wholesaling. It found serious misconduct and impaired fitness to practise, but rejected one allegation of dishonesty about regulatory approval of an agent. Recognising remorse and positive clinical references, it chose suspension with review rather than removal. No actual patient harm was found.
Charges
The allegations concerned repeated dishonesty in obtaining medicines for wholesaling through false prescriptions, forged signatures and misleading statements between 2019 and 2021, and two statements made in response to the regulatory investigation.
Findings
The committee found serious misconduct and impaired fitness to practise, with limited insight and insufficient remediation. It found dishonesty concerning claimed prolonged hospital negotiations but rejected dishonesty concerning the registrant's belief that an agent had MHRA approval. It found no actual patient harm and concluded the case fell short of requiring removal, imposing twelve months' suspension with review and an interim suspension during the appeal period.
Mitigating and aggravating factors
Mitigating factors
● R1 has demonstrated remorse ● R1 admitted the majority of his wrongdoing, including dishonesty, prior to this hearing ● R1 has no previous fitness to practise findings ● R1 has shown some insight into his misconduct ● R1 has provided testimonials from patients which make clear that he is well thought of as a pharmacist and is providing a valuable service to the community.
Aggravating factors
● R1’s dishonesty was premeditated, going to extraordinary lengths such as drafting a false SLA, inventing a patient in the Middle East and creating a false doctor’s letter. ● The dishonesty was for personal, financial gain. ● The dishonesty was repeated over the course of two to three years. ● The dishonesty took many forms and in different settings. ● R1 has only shown limited insight into his misconduct.
Source
All facts on this page are drawn from the publicly published General Pharmaceutical Council determination linked below. MedicWatch does not editorialise the regulator’s findings.
Spot something incorrect?
If a fact on this page is wrong, or you believe the page should not be published, please submit a correction or takedown request.